According to the company, the technology transfer expands an ongoing collaboration with Eli Lilly and Company, which was established in 2010.
As part of the agreement, Lilly will receive an exclusive, custom human antibody library, as well as a license to use the Adimab Platform in all therapeutic areas – without target restriction.
Additionally, Lilly has secured options to receive continued improvements to the Adimab Platform, including access to new antibody libraries.
Adimab will receive an undisclosed upfront fee and future payments dependent on achieving set preclinical and clinical milestones. The company will also receive royalties on any therapeutic products that result from the technology’s use.
Adimab has established partnerships with 50 pharmaceutical and biotechnology companies over the past eight years and has also transferred and implemented its technology at Merck, Novo Nordisk, Biogen, and GSK.
According to the company's mid-year partnership activity update, its most advanced program with partner Arsanis is currently in Ph II clinical trials.
New alliances this year include Anokion, Moderna Therapeutics, Mapp Biopharmaceutical, and Pionyr Immunotherapeutics, among others.